Cystic fibrosis is the most common, life-threatening, autosomal recessive disease in the Caucasian population. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator gene, which encodes a chloride ion channel expressed on the surface of epithelial cells. There are more than 2000 variants of the cystic fibrosis transmembrane conductance regulator gene reported worldwide. Some of these variants cause classic cystic fibrosis, while others are labeled as variants of unknown significance or variants of varying clinical consequences alleles and associated with atypical disease or cystic fibrosis transmembrane conductance regulator-related disorders. Although these alleles do not directly cause cystic fibrosis, they may predispose compound heterozygous patients to certain clinical phenotypes. Specifically, 1677delTA has been reported as a pathogenic allele in homozygous state or in combination with other cystic fibrosis-causing alleles. However, the L997F allele is considered to be benign or causative of non-classic cystic fibrosis or cystic fibrosis transmembrane conductance regulator-related disorders in combination with other pathogenic alleles. In this case series, we describe three cases with 1677delTA and L997F genotype, and speculate that a co-concurrence of these two alleles in does not cause classic cystic fibrosis symptoms; however, because the late-onset of cystic fibrosis is possible in the presence of rare alleles, such as L997F, longer follow-up of these patients and identification of a greater number of adults with 1677delTA/L997F genotype are necessary to make final conclusion about the nature of this genotype.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233568PMC
http://dx.doi.org/10.1177/2050313X231177163DOI Listing

Publication Analysis

Top Keywords

cystic fibrosis
40
fibrosis transmembrane
16
transmembrane conductance
16
cystic
11
fibrosis
10
disease cystic
8
conductance regulator
8
regulator gene
8
classic cystic
8
conductance regulator-related
8

Similar Publications

Palliative care needs in cystic fibrosis: hospital survey.

BMJ Support Palliat Care

December 2024

Section of Palliative Medicine, Department of Oncology, Rigshospitalet, Kobenhavn, Denmark

Background: Cystic fibrosis (CF) is an incurable, progressive disease that affects multiple organs, causing burdensome symptoms. This study aimed to explore the palliative care needs in patients with CF, focusing on health-related quality of life (HRQOL), fatigue, anxiety and depression.

Methods: From October 2019 to March 2020, a cross-sectional questionnaire survey was conducted with outpatients with CF at the Infectious Medicine Clinic in a Danish University Hospital.

View Article and Find Full Text PDF

Cystic fibrosis carrier screening in Australia: comparing sequencing and targeted panels across diverse ancestries.

J Med Genet

December 2024

Molecular Genetics, Virtus Diagnostics, Revesby, New South Wales, Australia.

Background: Targeted cystic fibrosis (CF) carrier screening panels may lack sensitivity in non-European ancestry groups. This study aims to evaluate the sensitivity of various panels in Australian CF carriers identified through sequencing.

Methods: The following panels were evaluated in 869 CF carriers: Asuragen, Elucigene, Devyser, American College of Medical Genetics and Genomics and Victorian Clinical Genetics Services.

View Article and Find Full Text PDF

Immunomodulatory therapy by macrolides: More than killing bugs.

Pediatr Pulmonol

December 2024

Department of Pediatrics and Professor of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia, USA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!